A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer Defined as Primary Tumor That is Her2-neu and Low (< 10%) ER/PR Nuclear Staining

Trial Profile

A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer Defined as Primary Tumor That is Her2-neu and Low (< 10%) ER/PR Nuclear Staining

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Sep 2017

At a glance

  • Drugs TPIV 200 (Primary) ; Cyclophosphamide
  • Indications Breast cancer
  • Focus Pharmacodynamics; Proof of concept
  • Sponsors TapImmune
  • Most Recent Events

    • 27 Jun 2017 According to a TapImmune media release, the company has enrolled 50% of patients in this study.
    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top